Georgia's Online Cancer Information Center

Multiple Myeloma Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Multiple Myeloma
Cancer Type = Multiple Myeloma
There are currently 55 active Multiple Myeloma clinical trials in Georgia.
1.
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Cancer Type
Multiple Myeloma
NCT ID
NCT03374085
Protocol IDs
CC-92480-MM-001
NCI-2018-00132
U1111-1205-3650
2017-001236-19
Treatment Sites (1)
Emory Clinic
Atlanta
2.
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04910568
Protocol IDs
GO42552
NCI-2021-07543
2021-000238-33
3.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04133636
Protocol IDs
CR108581
2018-004124-10
68284528MMY2003
NCI-2019-07363
4.
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03215030
Protocol IDs
TAK-573-1501
NCI-2017-01894
U1111-1195-8134
TV48573-ONC-10128
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Cancer Type
Hematopoietic Malignancies, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05050097
Protocol IDs
CR108946
NCI-2021-13605
2020-004502-55
64407564MMY1004
6.
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04722146
Protocol IDs
CR108927
NCI-2021-02225
64007957MMY1004
2020-004404-33
7.
A Study of WVT078 in Patients With Multiple Myeloma (MM)
Cancer Type
Multiple Myeloma
NCT ID
NCT04123418
Protocol IDs
CWVT078A12101
NCI-2021-09189
8.
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03287908
Protocol IDs
20170122
NCI-2017-02084
2017-001997-41
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT02773030
Protocol IDs
CC-220-MM-001
NCI-2016-01463
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03601078
Protocol IDs
BB2121-MM-002
NCI-2018-01730
U1111-1216-4209
2018-000264-28
Treatment Sites (1)
13.
Battery Powered Drill versus Conventional Methods in Comparing Quality of Bone Marrow Biopsy, Convenience, and Pain Control in Patients with Plasma Cell Disorders
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03078452
Protocol IDs
Winship2656-14
NCI-2017-00308
IRB00075658
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
14.
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT04955808
Protocol IDs
DCP-002
DCP-002
DCP-002
NCI-2017-01572
15.
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients with High-Risk Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03756896
Protocol IDs
Winship4101-17
NCI-2017-02052
IRB00097882
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
16.
Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant
Cancer Type
Lymphoma, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05274763
Protocol IDs
EU5492-21
NCI-2022-00233
STUDY00003563
17.
Collection and Storage of Tissue and Blood Samples from Patients with Cancer
Cancer Type
Lymphoma, Multiple Myeloma, Plasma cell neoplasm, Solid Tumor
NCT ID
NCT02474160
Protocol IDs
9846
9846
NCI-2015-00863
P9846
P9846_R02PAPPHOLD01
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
18.
Daratumumab, Ixazomib, and Dexamethasone with or without Bortezomib in Treating Patients with Newly Diagnosed Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03942224
Protocol IDs
Winship4547-18
NCI-2018-03615
IRB00102336
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
19.
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma with Kidney Failure
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04352205
Protocol IDs
WINSHIP4949-20
NCI-2020-01133
NCI-2020-01133
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
20.
Denosumab in Treating Patients with Multiple Myeloma with Kidney Insufficiency
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT02833610
Protocol IDs
15-571
NCI-2016-01375
Treatment Sites (1)
21.
Depleted Immune Suppressor Stem Cell Transplant in Enhancing Immune Response to Vaccines in Patients with Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT02700841
Protocol IDs
WINSHIP2905-15
NCI-2015-00743
IRB00079982
22.
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03399799
Protocol IDs
CR108404
NCI-2018-00367
64407564MMY1001
2017-002400-26
23.
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03145181
Protocol IDs
CR108206
NCI-2017-01157
64007957MMY1001
2016-002122-36
24.
NCORP Trial
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Cancer Type
Multiple Myeloma
NCT ID
NCT03651128
Protocol IDs
BB2121-MM-003
2018-001023-38
NCI-2018-02057
U1111-1217-9988
Treatment Sites (2)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
25.
First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03761108
Protocol IDs
R5458-ONC-1826
NCI-2019-02952
2018-003188-78
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
26.
Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04776395
Protocol IDs
WINSHIP5157-20
NCI-2020-08351
27.
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Cancer Type
Multiple Myeloma
NCT ID
NCT04150965
Protocol IDs
MyCheckpoint (MMRC-089)
MMRC-089 Anti LAG3/Anti TIGIT
NCI-2019-07957
Treatment Sites (1)
28.
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients with Multiple Myeloma
Cancer Type
Bone Tumor, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03858205
Protocol IDs
16M-18-2
NCI-2018-03600
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
29.
Melphalan before Stem Cell Transplant for the Treatment of Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04483206
Protocol IDs
WINSHIP5001-20
NCI-2020-04920
STUDY00000449
30.
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Cancer Type
Multiple Myeloma
NCT ID
NCT03732703
Protocol IDs
MyDRUG (MMRC-085)
NCI-2019-00698
Treatment Sites (1)
31.
NCORP Trial
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type
Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Solid Tumor
NCT ID
NCT04314401
Protocol IDs
10323
10323
NCI-2020-00750
Treatment Sites (18)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
32.
NFKB2 Rearrangement in Guiding Treatment with Ixazomib Citrate and Dexamethasone or Ixazomib Citrate, Dexamethasone and Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT02765854
Protocol IDs
MMRC060
NCI-2016-00043
IRB00077815
Treatment Sites (2)
Gordon Hospital
Calhoun
Lanell Jacobs
706-879-5852
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
33.
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma
NCT ID
NCT04136756
Protocol IDs
18-255-02
NCI-2019-07642
34.
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05204160
Protocol IDs
Winship5388-21
NCI-2021-08718
STUDY00003182
36.
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Cancer Type
Multiple Myeloma
NCT ID
NCT01838512
Protocol IDs
CA204-008
Treatment Sites (2)
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
38.
Rifaximin in Treating Patients with Monoclonal Gammopathy
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03820817
Protocol IDs
Winship4480-18
NCI-2018-02106
IRB00106380
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
39.
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04855136
Protocol IDs
BB2121-MM-007
NCI-2021-07135
2020-003248-10
40.
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04445701
Protocol IDs
AO-176-102
NCI-2020-11628
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
41.
Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.
Cancer Type
Hematopoietic Malignancies, Leukemia, Multiple Myeloma, Myelodysplastic Syndromes (MDS)
NCT ID
NCT03218683
Protocol IDs
D6910C00001
NCI-2017-01390
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
42.
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Cancer Type
Leukemia, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03486067
Protocol IDs
CC-93269-MM-001
NCI-2018-02280
2017-003448-19
U1111-1210-6325
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
43.
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
Cancer Type
Leukemia, Multiple Myeloma
NCT ID
NCT02952508
Protocol IDs
DCL-16-001
NCI-2017-01758
44.
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type
Hematopoietic Malignancies, Multiple Myeloma, Non-Hodgkin Lymphoma
NCT ID
NCT03424603
Protocol IDs
STRO-001-BCM1
NCI-2018-00484
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
45.
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
Cancer Type
Multiple Myeloma
NCT ID
NCT02899052
Protocol IDs
M15-538
NCI-2016-01672
Treatment Sites (1)
46.
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04879043
Protocol IDs
HDP-101-01
NCI-2021-04304
47.
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma
NCT ID
NCT04756726
Protocol IDs
CFT7455-1101
NCI-2021-05587
50.
NCORP Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm
NCT ID
NCT02693535
Protocol IDs
Pro00014171
NCI-2017-00510
Treatment Sites (3)
51.
NCORP Trial NCI Priority
Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type
Bladder Cancer, Brain & Spinal Cord Tumor, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Plasma cell neoplasm, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Thyroid Cancer, Unknown Primary, Uterine Cancer
NCT ID
NCT02465060
Protocol IDs
EAY131
NCI-2015-00054
EAY131-A
EAY131-B
EAY131-E
EAY131-F
EAY131-G
EAY131-H
EAY131-Q
EAY131-R
EAY131-U
EAY131-V
Treatment Sites (29)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
52.
53.
NCORP Trial
Testing the Addition of Daratumumab-Hyaluronidase to Enhance Therapeutic Effectiveness of Lenalidomide in Smoldering Multiple Myeloma, The DETER-SMM Trial
Cancer Type
Multiple Myeloma
NCT ID
NCT03937635
Protocol IDs
EAA173
EAA173
NCI-2018-02611
Treatment Sites (1)
54.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Plasma cell neoplasm
NCT ID
NCT03805789
Protocol IDs
CSL964_2001
NCI-2019-03310
2018-000329-29
Treatment Sites (1)
55.
Trametinib with or without Dabrafenib Mesylate in Treating Patients with BRAF, KRAS, or NRAS Gene Mutation and Recurrent Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03091257
Protocol IDs
16-352
NCI-2017-01202
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.